Please assess the completion status of the following clinical trial:

Trial Title: Cromoglicate in Mastocytosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent has been obtained~* Chronic stable symptomatic maculopapulous cutaneous mastocytosis or indolent systemic mastocytosis with skin involvement and a positive Darier's Sign~* Age between 18 and 70 years~* Either sex~* Any race or ethnicity~* Attending hospital outpatient clinic or the private practice of a dermatologist.~Exclusion Criteria:~* The presence of autoimmune and infectious disease including aggressive systemic mastocytosis~* Medical history or presence of epilepsy, significant neurological disorders, cerebrovascular attacks or ischemia~* Medical history or presence of myocardial infarction or cardiac arrhythmia which requires drug therapy, hyper/hypokalemia~* Evidence of severe renal dysfunction (creatinine \> 1,5 times upper reference value)~* Evidence of significant hepatic disease (liver enzymes \> 2 times upper reference value)~* Presence of active cancer which requires chemotherapy or radiation therapy~* Commitment to an institution in terms of § 40 Abs. 1 S. 3 Nr. 4 AMG~* Intake of antihistamines or leukotriene antagonists within 7 days prior to the beginning of the study~* Intake of oral corticosteroids within 14 days prior to randomisation~* Use of depot corticosteroids or chronic systemic corticosteroids within 21 days prior to randomisation~* Radiation therapy of target areas including UV therapy within 4 weeks prior to randomisation~* Confounding other dermatological diseases or conditions that can affect the symptoms of the target areas~* Known or suspected hypersensitivity to component(s) of investigational products.~* Current participation in any other interventional clinical trial.~* Subjects who have received treatment with any nonmarketed drug substance (i.e. an agent which has not yet been made available for clinical use following registration) within the last 4 weeks or 5 half-lives (whichever is longer) prior to randomisation~* Previously randomised in this clinical trial~* In the opinion of the investigator, the subject is unlikely to comply with the Clinical Study Protocol (e.g. alcoholism, drug dependency or psychotic state).~* Females who are pregnant, of child-bearing potential and wishing to become pregnant during the trial or are breast feeding.~* Females of child-bearing potential with positive pregnancy test at visit 1.~* Subjects (or their partner) not using an adequate method of contraception (according to national requirements, as applicable)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (left) / Cromoglicate (right) (Type: OTHER): Placebo (on a lesion left bodyside), Cromoglicate (on a lesion on right bodyside)
- Placebo (right) / Cromoglicate (left) (Type: OTHER): Placebo (on a lesion right bodyside), Cromoglicate (on a lesion on left bodyside)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues